Ruaro, B.; Gandin, I.; Pozzan, R.; Tavano, S.; Bozzi, C.; Hughes, M.; Kodric, M.; Cifaldi, R.; Lerda, S.; Confalonieri, M.;
et al. Nintedanib in Idiopathic Pulmonary Fibrosis: Tolerability and Safety in a Real Life Experience in a Single Centre in Patients also Treated with Oral Anticoagulant Therapy. Pharmaceuticals 2023, 16, 307.
https://doi.org/10.3390/ph16020307
AMA Style
Ruaro B, Gandin I, Pozzan R, Tavano S, Bozzi C, Hughes M, Kodric M, Cifaldi R, Lerda S, Confalonieri M,
et al. Nintedanib in Idiopathic Pulmonary Fibrosis: Tolerability and Safety in a Real Life Experience in a Single Centre in Patients also Treated with Oral Anticoagulant Therapy. Pharmaceuticals. 2023; 16(2):307.
https://doi.org/10.3390/ph16020307
Chicago/Turabian Style
Ruaro, Barbara, Ilaria Gandin, Riccardo Pozzan, Stefano Tavano, Chiara Bozzi, Michael Hughes, Metka Kodric, Rossella Cifaldi, Selene Lerda, Marco Confalonieri,
and et al. 2023. "Nintedanib in Idiopathic Pulmonary Fibrosis: Tolerability and Safety in a Real Life Experience in a Single Centre in Patients also Treated with Oral Anticoagulant Therapy" Pharmaceuticals 16, no. 2: 307.
https://doi.org/10.3390/ph16020307
APA Style
Ruaro, B., Gandin, I., Pozzan, R., Tavano, S., Bozzi, C., Hughes, M., Kodric, M., Cifaldi, R., Lerda, S., Confalonieri, M., Baratella, E., Confalonieri, P., & Salton, F.
(2023). Nintedanib in Idiopathic Pulmonary Fibrosis: Tolerability and Safety in a Real Life Experience in a Single Centre in Patients also Treated with Oral Anticoagulant Therapy. Pharmaceuticals, 16(2), 307.
https://doi.org/10.3390/ph16020307
